|
1
|
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS: Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 19:151–172. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gobbini E, Charles J, Toffart AC, Leccia MT, Moro-Sibilot D and Giaj Levra M: Current opinions in immune checkpoint inhibitors rechallenge in solid cancers. Crit Rev Oncol Hematol. 144:1028162019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S and Petrelli F: Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 165:1034342021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kagohashi K, Miyazaki K, Shiozawa T and Satoh H: Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient. Adv Respir Med. 89:316–319. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Plazy C, Hannani D and Gobbini E: Immune checkpoint inhibitor rechallenge and resumption: A systematic review. Curr Oncol Rep. 24:1095–1106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takemura K, Yamanaka T, Hayashida M, Kizawa R, Yamaguchi T, Tanabe Y, Sakaguchi K, Suyama K, Urakami S and Miura Y: Bell's palsy during rechallenge of immune checkpoint inhibitor. IJU Case Rep. 6:144–146. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu M, Hao Y, Shi Z and Song Z: Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 149:17987–17995. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D and Zimmer L: The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer. 155:268–280. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren Z, Ducreux M, Abou-Alfa GK, Merle P, Fang W, Edeline J, Li Z, Wu L, Assenat E, Hu S, et al: Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): A multicenter, non-randomized, open-label, phase 2 trial. Liver Cancer. 12:72–84. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boige V, Raoul JL, Pignon JP, Bouche O, Boucher E, Blanc JF, Seitz JF, Dupouy BN and Ducreux M; For the Fédération Francophone de Cancérologie Digestive, : Preliminary results of capecitabine-oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003-03 trial). J Clin Oncol. 23 (16 Suppl):S41282005. View Article : Google Scholar
|
|
11
|
Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng Z, Gu S, Wang L and Zou J: A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clin Oncol. 37 (15 Suppl):S40742019. View Article : Google Scholar
|
|
12
|
Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress of Anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC. Front Oncol. 12:7691242022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin X, Zong C, Zhang Z, Fang W and Xu P: Progresses in biomarkers for cancer immunotherapy. MedComm (2020). 4:e3872023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, Feng Y, Chen ZS and Wang N: Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 23:1892024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piñero F, Dirchwolf M and Pessôa MG: Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells. 9:13702020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Donnell JS, Long GV, Scolyer RA, Teng MWL and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 52:71–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Syn NL, Teng MWL, Mok TSK and Soo RA: De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18:e731–e741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Geng Z, Hao B and Geng Q: Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody. Cancer Control. 29:107327482211112962022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vogel A, Meyer T, Sapisochin G, Salem R and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu L, Zheng YH, Han L and Qin SK: Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies. Medicine (Baltimore). 95:e49932016. View Article : Google Scholar : PubMed/NCBI
|
